ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 41 filers reported holding ADC THERAPEUTICS SA in Q3 2023. The put-call ratio across all filers is 2.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,179 | -60.3% | 1,315 | -4.8% | 0.00% | – |
| Q2 2023 | $2,971 | -98.1% | 1,382 | -98.3% | 0.00% | – |
| Q1 2023 | $157,732 | -99.1% | 80,888 | -98.3% | 0.00% | -100.0% |
| Q4 2022 | $17,869,261 | -51.7% | 4,653,453 | -39.4% | 0.00% | -50.0% |
| Q3 2022 | $36,985,000 | -39.4% | 7,673,137 | -0.1% | 0.00% | -33.3% |
| Q2 2022 | $61,065,000 | -45.9% | 7,681,046 | 0.0% | 0.01% | -33.3% |
| Q1 2022 | $112,835,000 | -27.2% | 7,681,046 | +0.1% | 0.01% | -18.2% |
| Q4 2021 | $154,988,000 | -25.6% | 7,672,673 | 0.0% | 0.01% | -35.3% |
| Q3 2021 | $208,390,000 | +11.5% | 7,672,673 | 0.0% | 0.02% | +13.3% |
| Q2 2021 | $186,830,000 | -1.4% | 7,672,673 | -1.1% | 0.02% | -6.2% |
| Q1 2021 | $189,460,000 | -23.7% | 7,761,585 | 0.0% | 0.02% | -27.3% |
| Q4 2020 | $248,448,000 | -1.8% | 7,761,585 | +1.2% | 0.02% | -15.4% |
| Q3 2020 | $253,085,000 | +3.1% | 7,671,585 | +46.3% | 0.03% | -3.7% |
| Q2 2020 | $245,483,000 | – | 5,244,231 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,680,149 | $33,939,000 | 9.12% |
| Redmile Group, LLC | 7,451,029 | $150,511,000 | 3.42% |
| Grosvenor Holdings, L.L.C. | 1,517,212 | $30,648,000 | 3.17% |
| Indie Asset Partners, LLC | 96,582 | $1,951,000 | 1.42% |
| MPM BioImpact LLC | 337,396 | $6,815,000 | 1.24% |
| Eventide Asset Management | 1,975,000 | $39,895,000 | 0.51% |
| HHLR ADVISORS, LTD. | 500,000 | $10,100,000 | 0.16% |
| Virtus ETF Advisers LLC | 19,193 | $388,000 | 0.15% |
| CNA FINANCIAL CORP | 15,245 | $308,000 | 0.08% |
| Employees Retirement System of Texas | 278,000 | $5,616,000 | 0.06% |